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The role of prostaglandin (PG) F2a has been scarcely studied in cancer. We have identified a new function for PGF2a in ovarian
cancer, stimulating the production of Prostate Transmembrane Protein, Androgen Induced 1 (PMEPA1). We show that this induc-
tion increases cell plasticity and proliferation, enhancing tumor growth through PMEPA1. Thus, PMEPA1 overexpression in ovarian
carcinoma cells, significantly increased cell proliferation rates, whereas PMEPA1 silencing decreased proliferation. In addition,
PMEPA1 overexpression buffered TGF signaling, via reduction of SMADdependent signaling. PMEPA1 overexpressing cells
acquired an epithelial morphology, associated with higher Ecadherin expression levels while catenin nuclear translocation was inhib-
ited. Notwithstanding, high PMEPA1 levels also correlated with epithelial to mesenchymal transition markers, such as vimentin and
ZEB1, allowing the cells to take advantage of both epithelial and mesenchymal characteristics, gaining in cell plasticity and adapt-
ability. Interestingly, in mouse xenografts, PMEPA1 overexpressing ovarian cells had a clear survival and proliferative advantage,
resulting in higher metastatic capacity, while PMEPA1 silencing had the opposite effect. Furthermore, high PMEPA1 expression
in a cohort of advanced ovarian cancer patients was observed, correlating with Ecadherin expression. Most importantly, high
PMEPA1 mRNA levels were associated with lower patient survival.
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Introduction
Prostaglandin F2a (PGF2a) is an arachidonate biosynthetic pathway
endproduct, which ratelimiting step is catalyzed by cyclooxygenases
(COX), enzymes implicated in various disease states including cancer
[1]. PGF2a has been scarcely studied on cancer although it has been
detected in several tumor types and cancer patient body fluids [24],
recently has been mechanistically associated with colon cancer progression
[5].
Previous studies have shown increases of COX, prostaglandin syn-
thases, prostaglandins and receptors in epithelial ovarian cancer (EOC)
[6,7]. EOC, which comprises 90% of all ovarian malignancies, is the lead-
ing cause of death from gynecological cancer, due to late diagnosis, in
developed countries [8,9].
PMEPA1 gene expression has been found in several primary and meta-
static tumor types [1012]. Depending on the tumor tissue origin,
PMEPA1 has been shown to have a protumor or antimetastatic role. Thus,
in prostate cancer, it is well established as a part of a negative feedback
loop of the Androgen Receptor (AR), which induces PMEPA1, that par-
ticipates in the degradation of the receptor through an E3 ubiquitin ligase
complex [13]. Depending on whether the prostate cancer cells are positive
or negative to AR, PMEPA1 has a growth inhibitory or a
growthpromoting role [1317], while some studies have shown that it inhi-
bits prostate cancer metastases to bone [14]. On the other hand, PMEPA1
has been already shown to have protumorigenic effects y breast and lung
cancer [1821] and high expression levels in other types, such as kidney and
colorectal cancer [10,22,23]. PMEPA1 can also be induced by transform-
ing growth factor (TGF) [10]. PMEPA1 downregulates TGF signaling by
sequestering RSMAD and promoting lysosomal degradation of TGF
receptor [24]. PMEPA1, through a negative feedback loop, is described
to switch TGF from tumor suppressor to tumor promoter in breast cancer
[12]. In addition, TGFdependent growth of aggressive breast cancer has
been suggested to depend on increased expression of PMEPA1 gene
[11]. TGF has been implicated in physiological and pathological processes
in the ovary [25,26]. In ovarian cancer, TGF has been shown to control
cell proliferation [27].
Here, we identify, PMEPA1 as a COX2/PGF2a upregulated gene
through the induction of TGF and we have deciphered its role in ovarian
cancer progression. We have found that PGF2a induced TGFB1 and
PMEPA1 and we provide new evidence of its important role in ovarian
cancer progression. Moreover, our results indicate that PMEPA1 is a crit-
ical regulator of epithelial plasticity, conferring a growth advantage in ovar-
ian cancer cells.
Materials and methods
Ovarian samples
A series of 19 normal, 51 primary tumors and 37 metastatic/relapse
ovarian samples were collected at the MD Anderson Cancer Center Bio-
bank (Madrid; record number B.0000745, ISCIII National Biobank
Record), the centers ethical committee approved the study, and a complete
written informed consent was obtained from all patients. The sample char-
acterization was performed by a pathologist (ARS), who determined the
histological cancer subtype according to the World Health Organization
(WHO) criteria [28], and the stage and grade (Supplemental Table 1).
Cell lines
SKOV3lucD6 cells, stably expressing Firefly Luciferase, were obtained
from Caliper Life Sciences. SKOV3 and TOV112D cells were from
ATCC and A2780 cell line was provided by SigmaAldrich. OVCAR8 cell
line was a gift from Dr. JM Cuezva (CBMSO). All cell lines were grown in
the recommended conditions.
Reagents
All generic reagents were from Invitrogen or SigmaAldrich. Oligonu-
cleotide and antibody details can be found in Supplementary Tables 2
and 3. Plasmids and Lentiviral vector transduction methods are listed in
Supplementary Materials and Methods.
Cell assays
Cell proliferation assays were performed plating 20,000 cells in various
35 mm wells and each day of the experiment cells from a different well
were counted. Growth was also quantified by Crystal Violet staining: Glu-
taraldehyde fixed cells were stained with 0.5% Crystal Violet/50% metha-
nol for 20. Stain was dissolved in 10% Acetic Acid after washing and O.D.
measured at 570 nm.
Substrate independent cell growth assays were performed by seeding
50,000 cells/well in ultralow attachment surface 24well plates (Costar)
in normal growth medium. At the end of the experiment relative cell num-
bers were estimated by Alamar Blue staining (Invitrogen).
RNA isolation and RTqPCR analysis were performed as described [5].
Immunofluorescence and Western blotting were performed as
described before [5]. Images were taken using a Zeiss Axioscop2 plus with
a color CCD camera or the Zeiss LSM710 confocal microscope. For
nuclear/cytoplasmic/membrane fractionation please see Supplemental
Methods. For WB, densitometry quantification of the bands obtained is
included in Supplementary Figures S6 and S8.
Luciferase assays were performed as described before [5].
Tumor growth in nude mice
In all cases, the minimum cell number indicated for each xenograft
model was used. In the case of A2780 and TOV122D cell lines, 106
and 5x104 cells were injected subcutaneously in 6 week old female
Rag2/Il2rg Double Knockout mice (R2G2, ENVIGO, France). For the
SKOV3Luc subcutaneous and intraperitoneal xenograft models,
6weekold female Swiss Nude mice (Crl:NU (Ico)Foxn1nu, Charles River
Laboratories) were injected with 1X106 cells, following the instructions
of the provider of the cells, Caliper LS. Mice were weighted once a week
and the tumor volume was estimated with a digital caliper by measuring:
length width height. Tumor growth estimation was made as described
before [5,29] using a Xenogen IVIS Lumina CCD camera (Caliper Life
Sciences). In the orthotopic mouse model of ovarian cancer, animals were
injected with 5x105 in the left ovary.
Histological analysis and immunohistochemistry
Tumors from mice and patients were fixed in 4% phosphate buffered
formalin (pH 7.4) and 2 m paraffinembedded sections were immunos-
tained, performed as previously described [5,29]. Antibodies used for
immunohistochemistry: antiPMEPA1 (1:50) as primary antibody
(SigmaAldrich) and secondary antibody conjugated with HRP (Envi-
sion + Dual link System HRP, Dako). Finally, sections were developed
using DAB solution (Liquid DAB + substrate chromogen system, DAKO
K3468) and images were taken with a LEICA DMD108 Digital
Microimaging Device (Leica Microsystems).
Databases and genomics analysis was performed through the UCSC
Xena Browser as indicated in Supplemental Methods.
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Statistical analysis
Results are expressed as mean SEM. The Students t test, the ANOVA
test or Welchs ttest were used for comparisons, where necessary. *p < 0.05
and **p < 0.01 denote statistical significance. For gene expression correla-
tion/covariance, Pearsons correlation coefficient was calculated. The statis-
tical analysis was performed using the GraphPad Prism 4.0 statistical
software.
Results
TGFB1 expression correlates with the COX2/PGF2a /NFAT pathway
TGF is a crucial factor for ovarian homeostasis and tumorigenesis [27].
Indeed, gene expression analysis of the TCGA TARGET GTEx patient
cohort RNA sequencing data using the UCSC XENA cancer browser
shows a 2fold increase of TGFB1 mRNA levels in ovarian tumor samples,
compared to normal ovarian tissue (Supplementary Figure S1A). PGF2a
has an important role in the female reproductive system and is known
to be produced in the ovary, as is produced also in ovarian tumors [7].
PGF2a binds and signals through the F prostaglandin receptor (FP,
PTGFR), a G protein coupled receptor, coupling mainly to Gq, thus lead-
ing to an increase in intracellular Ca2+ levels [30]. Consequently, PGF2a
binding to FP causes Ca2+/calcineurin activation NFAT transcription fac-
tors, implicated in a growing variety of physiological and pathological
functions, including cancer [31]. Interestingly, we found that PGF2a sig-
nificantly increased TGFB1 mRNA levels in ovarian serous adenocarci-
noma SKOV3 cells (Suppl. Figure S1B). TGFB1 mRNA levels
correlated to the PTGS2 (Pearsons r = 0.20, p < 0.0001, n = 369) and
PTGFR mRNA levels in ovarian tumors (Suppl. Figure S1C). On the
other hand, the calcineurin/NFAT activator Ca2+ ionophore A23287 sig-
nificantly increased TGFB1 mRNA levels in SKOV3 cells mimicking the
PGF2a effect (Suppl. Figure S1B). We found that NFATC2 is upregulated
more than 2 fold in ovarian tumors, compared to healthy tissue (Suppl.
Figure S1D). Moreover, NFATC2 and TGFB1 mRNA levels correlated
strongly (Suppl. Figure S1E), as did also NFATC1 and TGFB1 (Pearsons
rho = 0.41, p < 0.0001, n = 369). As expected, TGFB1 levels also corre-
lated with the RCAN1 levels (a bonafide NFAT transcriptional target)
mRNA levels (Suppl. Figure S1F).
Along these lines, multiple NFATc1 binding sites were identified in
the promoter region of TGFB1, using chromatin immunoprecipitation
and mass sequencing (ChIPseq) data experimental from the Gene Tran-
scription Regulation Database (GTRD), two of them in the TGFB1 gene
regulatory region located in its first intron (Suppl. Figure S2), Site IDs:
345418867, indicating a possible transcriptional regulation of TGFB1
by PGF2a/NFAT signaling. All these findings could indicate a close rela-
tionship between the COX2/PGF2a/FP/Ca
2+/NFAT pathway and
TGFB1.
PMEPA1 levels are elevated in patients ovarian tumor samples
PMEPA1 has been proposed as a TGF induced gene [12]. Indeed, we
found a strong correlation between TGFB1 and PMEPA1 mRNA levels in
the TCGA ovarian cancer cohort (Suppl. Figure S1G). A similar correla-
tion was found between PMEPA1 and RCAN1 mRNA levels (Suppl. Fig-
ure S1H), indicating the possible, direct or indirect, implication of NFAT
in the PMEPA1 gene expression. Additionally, we found tumor PMEPA1
mRNA levels to be significantly higher than in normal ovary (Suppl.
Figure S1I).
To confirm this, we performed immunohistochemistry on normal tis-
sue obtained from ovaries, as well as ovarian primary tumors and relapses.
Primary ovarian tumors showed strong PMEPA1 staining in tumor cells
compared to normal ovaries that showed diffuse expression in some
epithelial cells (Figure 1).
The patient cohort used for determining PMEPA1 protein levels
includes only highgrade tumors and most of them resulted positive for
PMEPA1. Thus, no significant differences in patient survival according
to PMEPA1 expression could be obtained. However, after analysis of
the gene expression databases available (TCGA ovarian cancer), high
PMEPA1 expression associated with lower survival probability (Suppl.
Figure S3). The above observations suggest PMEPA1 could have an
important role in ovarian cancer progression and it could be considered
as a potential biomarker for ovarian tumor characterization and patient
stratification.
Induction of PMEPA1 expression by PGF2a
Treatment of SKOV3, OVCAR8, TOV112D or A2780 ovarian can-
cer cells with fluprostenol, a metabolically stable PGF2a analog, increased
PMEPA1 mRNA levels, as did TGF treatment. The combination of both
treatments had a partially additive effect (Figure 2A). We transduced
Skov3 cells with lentiviral shRNA vectors to knockdown PTGFR mRNA,
thus decreasing PTGFR levels and signaling. When the resulting cell lines
were treated with PGF2a (Figure 2B) or fluprostenol (not shown) they
failed to increase PMEPA1 mRNA levels as the control scrambled shRNA
cells did, indicating that PMEPA1 induction depended on the PGF2a sig-
naling. Moreover, calcineurin/NFAT inhibition by cyclosporine A (CSA)
could revert PGF2ainduced TGFB1 and PMEPA1 increase (Figure 2C).
Indeed, CSA not only reverted significantly both genes induction, but also
reduced their levels in the absence of PGF2a, indicating a possible basal
Ca2+/calcineurin signaling. Interestingly, the PTGFR induction of
PMEPA1, but not RCAN1, a direct NFAT target, was reverted by
cotreatment with an inhibitor of TGF type I receptor, LY2109761 (Fig-
ure 2D), indicating that basal TGFR signaling may be necessary for basal
and Ca2+ stimulated PMEPA1 expression.
We then analyzed PMEPA1 transcriptional activity, using two lucifer-
ase reporter constructs: the PMEPA1 promoter fragment 1972PMEPA1-
luc and PMEPA1 first intron pGL3ti850 [32]. In SKOV3 cells,
pGL3ti850 activity was stimulated by TGF treatment but not by flupros-
tenol alone, although it showed a strong synergistic activity with TGF. On
the other hand, 1972PMEPA1luc was only activated by the combination
of fluprostenol and TGF (Figure 2E). These results would indicate that
SMADs and NFAT cooperatively stimulate PMEPA1 mRNA expression,
while the PGF2a induction of PMEPA1 could be also partially due to
TGFB1 induction.
We searched the GTRD ChIPseq data and identified multiple
NFATc1 binding sites, Site IDs 2498230711, in the promoter and the
first intron regulatory region of PMEPA1. Interestingly, we found several
SMAD2, SMAD3 binding sites adjacent to the NFATc1 ones (Suppl.
Figure S4).
All the above suggest a cooperation of NFAT with SMADs for
PMEPA1 induction, pointing to is a positive feedback loop between
PGF2a/NFAT and TGF for PMEPA1 expression. TGF induced PMEPA1
expression can be further potentiated by the PGF2a/Ca
2+/CaN pathway,
both through its main promoter as by the first intron enhancer.
PMEPA1 overexpression in cancer cells enhances cell growth
To investigate the biological effects of PMEPA1 in tumor cells, we gen-
erated ovarian cancer cell lines (Skov3, OVCAR8, A2780 and
TOV112D), stably overexpressing PMEPA1 and compared them with
control cells carrying the empty vector (EV). Additionally, 5 PMEPA1
knockdown SKOV3Luc cell lines were generated. Knockdown or overex-
pression were confirmed by RTqPCR, WB and immunocytochemistry of
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thin layer preparations (Suppl. Figure S5). Interestingly, SKOV3 cells
had a higher proliferative rate than SKOV3EV cells (Figure 3A). Sim-
ilar results were obtained in PMEPA1 overexpressing A2780 and
TOV112D (Figure 3B). PCNA protein levels increased accordingly,
in agreement to this increased proliferation rate (Figure 4B). However,
no difference in growth was observed in OVCAR8 cells (not shown).
In contrast, proliferation rates of PMEPA1 knockdown cells were much
lower compared to scrambled (SCR) control cells (Figure 3A). Anchor-
age independent survival revealed that PMEPA1 overexpressing cells
survived better and formed bigger clusters that grew faster than EV cells
(Figure 3C and D).
PMEPA1 overexpression favors a partially epithelial phenotype
SKOV3 ovarian cells have been classified as intermediate mesenchymal
phenotype cells [33], in agreement with the fibroblastlike morphology the
cells have in culture, and TOV112D and A2780 as mesenchymal whereas
OVCAR8 cells are classified as epithelial. Once SKOV3 cells were trans-
duced with the PMEPA1 expression vector, morphological changes began
to be noticeable towards a more epithelial phenotype (Figure 4A). We
observed similar changes to an epithelial phenotype in A2780 and
TOV112D upon PMEPA1 transfection while but no changes in trans-
duced already epithelial OVCAR8 cells. The intercellular junction
Figure 1. PMEPA1 expression is widely expressed in ovarian cancer. Representative images of PMEPA1 (top), E-cadherin (middle), and beta-catenin
(down) expression by immunohistochemistry in normal A, and primary ovarian tumors B. Magnification 40x, inset 63x. The magnification areas are
highlighted in the square. C. Quantitative analysis of PMEPA expression in normal, primary tumor and metastasis/relapse ovarian samples. The
significance of the differences observed between the different groups was determined with a Chi-Square test P < 0.0001.
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Ecadherin expression was higher in PMEPA1 overexpressing cells (Fig-
ure 4B). This is in agreement with our finding that most ovarian tumors
tested express both PMEPA1 and Ecadherin (Figure 1) and supported by
the fact that CDH1 is 40fold more expressed in ovarian tumors as com-
pared to normal ovarian tissue (Suppl. Figure S7).
The interaction between the Ecadherin and the WNT signaling path-
way member leads to the retention of catenin in the cell membrane prox-
imity [34]. Thus, we next studied catenin protein subcellular localization
in PMEPA1 overexpressing cells. catenin localized both in the cytoplasm
and nucleus of SKOV3EV cells, while in PMEPA1 overexpressing cells it
had a perinuclear localization as well as in cellcell contacts, where
Ecadherin is localized (Figure 4C, D). As expected, TGF treatment
induced translocation of catenin to the nucleus in SKOV3 cells, while this
effect was absent when PMEPA1 was overexpressed (Figure 4C, D). Both
the mesenchymal phenotype and catenin dissociation from the membrane
of SKOV3 cells could be due to autocrine or paracrine TGF signaling,
since a TGF blocking antibody (Figure 4C) or the LY2109761 TGFRI
inhibitor (not shown) also caused catenin membrane localization and a
change to epitheliallike morphology. Surprisingly, Ecadherin expression
was not affected by TGF treatment in PMEPA1 cells (Figure 4D). On
Figure 2. PMEPA1 is upregulated by cooperative action of TGF and PGF2a. A. PMEPA1 mRNA levels quantification in the cells indicated after 24 h of
treatment with vehicle (CT), 1 M fluprostenol (flup), 5 ng/ml TGF, and the combination of the two (Flup + TGF). B. PMEPA1 and PTGFR mRNA
levels quantification in SKOV3 derived cell lines stably expressing a scrambled shRNA (scr) or three PTGFR specific shRNAs (FP19, FP55, FP86) after
24 h of treatment with vehicle (CT) or 1 M PGF2a. Only scr cells were able to significantly increase (*: p < 0.05) PMEPA1 mRNA with PGF2a
treatment. C. PMEPA1, TGFB1 and RCAN1 mRNA levels quantification in SKOV3 cells after 24 h of treatment with vehicle (CT), 1 M PGF2a,
100 ng/ml cyclosporine A (CSA) or combination of the two. CSA significantly reduced the levels of the three genes below the control levels (p < 0.05).
PGF2a significantly increased the three genes levels, while the combination of the two reduced the levels of the three genes, although in the case of
TGFB1, the levels were significantly different from CT as well as from PGF2a. D. PMEPA1 and RCAN1 mRNA levels quantification in SKOV3 cells
after 24 h of treatment with vehicle (CT), 1 M Flup, 1 mM A23187 Ca2+ ionophore (IO), 10 M LY2109761 (LY) or combinations. Both genes are
induced by Flup or IO (p < 0.05). LY treatment only affects PMEPA1 levels reducing them below CT levels, even in combined treatments (p < 0.05). E.
Luciferase reporter assays with SKOV3 cells transfected with the mentioned reporter constructs of the PMEPA1 promoter, and treated as shown for 24.
TGF- treatment only activated the PMEPA Ti 850 reporter (p < 0.05), while the combination of Flup and TGF- activated both reporters (p < 0.001). IO
or Flup alone did not have any activating effect.
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Figure 3. PMEPA1 overexpression in ovarian cancer cells enhances cell proliferation. A. Cell proliferation of 2 PMEPA1 overexpressing clonal SKOVE3
cell lines (left panel) and 5 knockdown (right panel) SKOV3 cell lines was estimated by cell counting using a hemocytometer. Average SEM are shown,
n = 5. Growth curves were significantly different, p = 0.025 for overexpressing vs control and P < 0.001 for knockdown vs SCR. These results were also
confirmed by crystal violet stain quantification of SKOV3 (not shown), A2780 and TOV112D EV and PMEPA cells (B). C. Anchorage independent
growth assays were performed with PMEPA1 overexpressing and control A2780 and SKOV3 cells that were monitored by light microscopy.
Representative photos of the cells at 72 h after seeding are shown. Bars: 50 m. D. Cell survival and proliferation in the assays in (C) was estimated at 96 h
after plating by Alamar blue assay. Stain reduction quantification is shown for A2780 and Skov3Luc. Average SEM are shown, n = 3.
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the other hand, PMEPA1 overexpression caused an 8fold induction in
SKOV3 cells. This fact was not contrary to the strong induction of
ZEB1 and Vimentin mRNA in PMEPA1 overexpressing cells, while
SNAI1 and 2 mRNA levels do not vary. In the same sense, we found that
PMEPA1 mRNA levels positively correlated with the levels of two ovarian
cancer cell EMT signatures as calculated using the TCGA Ovarian Cancer
data (Suppl. Figure 9). These results indicate that PMEPA1 overexpres-
sion can revert downregulation of Ecadherin in ovarian cancer cells and
decrease nuclear catenin by TGF.
The relationship between PMEPA1, Ecadherin and catenin, is also
supported by the finding that biopsies with high PMEPA1 levels, also
express Ecadherin and catenin. catenin was in most cases detected in
the plasma membrane and not nuclear (Figure 1). These results support
in vitro experiments, indicating that PMEPA1 high expression coincides
with Ecadherin expression and blocks catenin nuclear translocation in
ovary patients tumors.
PMEPA1 overexpression affects the TGF- signaling pathway
Increased phosphorylation of SMAD1/5/8 and SMAD2/3 was
observed in PMEPA1 overexpressing unstimulated cells while the fold
increase in SMAD phosphorylation after TGF treatment was less pro-
nounced in the case of SKOV3PMEPA1 cells (Figure 5A). On the other
hand, we detected high levels of SMAD2/3 and PSMAD2/3 proteins in
SKOV3shPMEPA1 compared to SCR and the opposite situation in the
case of pSMAD1/5/8, observing lower phosphorylation levels in knock-
down cells as compared to SCR (Figure 5B. For quantifications of the
blots please see Suppl. Figure S8). Interestingly, reduced levels of
SMAD2/3 in nuclear extracts were found in SKOV3PMEPA1 cells, while
the membrane bound SMAD2/3 increased (Figure 5C). Besides, we tested
if PMEPA1 affected SMADdependent transcription of TGFtarget genes.
PMEPA1 overexpression decreased EDN1 and CDKN1A mRNA levels
(Figure 5D), while its knockdown showed a tendency to increase SER-
Figure 4. PMEPA1 overexpression favors a partially epithelial phenotype. A. Light microscopy images of SKOV3 and TOV112D -EV and PMEPA1
cells in culture. Bars: 50 m. B. WB for the indicated proteins in SKOV3, A2780 and TOV112D -PMEPA1 and -EV cells. C. Immunofluorescence for -
catenin of SKOV3-PMEPA1 and SKOV3-EV (EV) cells. Cells were treated with 5 ng/ml of TGF- or combination of 10 g/ml of recombinant Latency
Associated Peptide (LAP-TGF-) and 5 ng/ml of TGF- for 24 h. Arrows indicate -catenin localization in cell-cell contacts. D. WB to detect the indicated
proteins in nuclear, membrane and cytoplasmic extracts of the SKOV3-lucD6 EV and SKOV3-PMEPA1 cells. E. qRT-PCR analysis of relative mRNA
levels of PMEPA1 and CDH1 (E-cadherin) in SKOV3-EV and PMEPA1 overexpressing cells. F. qRT-PCR analysis of relative mRNA levels of ZEB1,
VIM, SNAI1 and SNAI2 (coding for Zinc Finger E-Box Binding Homeobox 1, vimentin, SNAIL and SLUG respectively) in SKOV3-EV and PMEPA1
overexpressing cells.
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PINE1, EDN1 and CDKN1A (Figure 5E). These results indicate that
PMEPA1 can modulate the TGF pathway output in ovarian cancer cells.
PMEPA1 promotes tumor growth in vivo
Finally, to confirm that PMEPA1 promotes ovarian tumor growth, we
tested PMEPA1 overexpressing or knockdown cell lines growth in mice
(Figure 6). We used several xenograft mouse models to address different
aspects of ovarian cancer growth and metastasis. In the case of subcuta-
neous xenografts, SKOV3PMEPA1 tumor volume growth was much
higher compared to SKOVEV derived tumors that only became palpable
around day 55 (Figure 6A). Monitoring tumor bioluminescence we found
a growth advantage of SKOV3PMEPA1 over SKOV3EV xenografts from
the beginning of the experiment (Figure 6B). At the end of the experi-
ment, we extracted tumors to corroborate the mentioned results (Suppl.
Figure 10). SKOV3EV derived tumors were smaller; in some cases, we
were not able to isolate a tumor mass, although we could detect biolumi-
nescent signal. We confirmed these results, performing a similar experi-
ment, of subcutaneous injection of TOV112D and A2780 control and
PMEPA1 overexpressing cells, in the more permissive R2G2 mice. In
the case of TOV112D cells, PMEPA1 overexpression duplicated tumor
initiation rates comparing to EV cells, PMEPA1 tumors grew faster, reach-
ing maximum allowed size at least a month earlier than the EV ones
(Suppl. Figure 11). On the other hand, only A2780PMEPA1 cells, but
not the EV, presented detectable growing tumors during a 15week mon-
itoring period (Suppl. Figure 11).
To investigate the effects of PMEPA1 on tumor cell peritoneal dissem-
ination, we injected intraperitoneally two SKOV3PMEPA1 cell lines and
Figure 5. PMEPA1 overexpression affects the TGF signaling pathway. SMAD1/5/8 and SMAD2/3 phosphorylation state as detected by WB in
overexpressing (A) and knockdown (B) SKOV3 cells and their appropriated controls treated or not with 5 ng/ml TGF- for 1 h. C. WB for SMAD2/3
protein levels in SKOV3-EV and -PMEPA1 cells nuclear, membrane and soluble extracts. Relative SERPINE1, EDN1 and CDKN1A (coding for PAI-1,
Endothelin and p21waf1 respectively) mRNA levels in PMEPA1 overexpressing (D) and knockdown (E) SKOV3 cells and their corresponding controls. *:
p < 0.05.
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SKOV3EV cells. SKOV3PMEPA1 xenografts had an important prolifer-
ative advantage, even more remarkable than in the subcutaneous experi-
ments (Figure 6C). To search for internal organ invasion, we extracted
some organs (stomach, intestine, spleen, kidneys and pancreas) and peri-
toneal membrane. In mice that harbored SKOV3PMEPA1,
bioluminescent signal could be detected in several internal organs, while
in SKOV3EV mice, all organs were negative (Suppl. Figure S9). Besides,
peritoneal walls of SKOV3PMEPA1 xenografts show localized lumines-
cence signals corresponding to established metastases (Suppl. Figure S12).
These results suggest that intraperitoneal dissemination and metastasis is
facilitated by PMEPA1 overexpression.
Finally, to recapitulate all the steps of ovarian cancer growth, dissemi-
nation and metastasis, cells were injected orthotopically into the ovary.
SKOV3PMEPA1 xenografts showed a strong growth advantage compared
with SKOV3EV, which could hardly form intraovary tumors (Figure 6D).
More importantly, shPMEPA1 SKOV3 grew less, reaching lower BLI sig-
Figure 6. PMEPA1 promotes tumor growth in vivo. A. Subcutaneous xenograft Skov3Luc-EV and -PMEPA1 tumor volume, measured once a week,
using a digital caliper. EV derived tumors became palpable around the 8th week post inoculation. B. Bioluminescence Imaging (BLI) quantification of the
xenografts in (A). C. Growth of intraperitoneal injected cells was measure by bioluminescence quantification with IVIS Lumina Imaging system.
Orthotopic tumor xenografts growth estimation through bioluminescence quantification of PMEPA1 overexpressing (D) and knockdown (E)
SKOV3Luc derived cell lines. Tumors were removed at 35 dpi, but BLI monitorization continued until day 63 in both experiments. F. IHC of tumors
derived from PMEPA1 overexpressing or knockdown SKOV3 cells, stained for the indicated proteins. Magnification x400. B,C,D: Results are
represented as logarithmic scale of Photons/sec/cm2/sr means SEM.
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nal levels than SCR and much less than SKOV3PMEPA1 xenografts (Fig-
ure 6E) indicating that even the low PMEPA1 levels of control cells are
important for tumor growth. Thus, the difference between overexpressing
and silencing PMEPA1 in SKOV3 cells resulted in about 20,000 fold in
growth as measured by bioluminescence intensity.
To investigate the potential for these cells to develop metastasis, ovaries
were removed on day 35 (red arrow) and mice were monitored for biolu-
minescence, indicating metastatic tumor growth. A week after the opera-
tion, bioluminescence could be detected again, indicating cells had already
metastasized (Figure 6E). Thus, PMEPA1 gives a clear advantage to ovar-
ian tumor cells to adapt and grow in all the tested conditions. These
in vivo results and the PMEPA1 expression in patient highgrade tumors
strongly suggest that PMEPA1 could be an accurate biomarker of progno-
sis in ovarian cancer.
Discussion
PGF2a has only recently been associated with tumor progression in col-
orectal [5,35] and endometrial cancer [36]. Since it is naturally produced
in the ovary and capable to produce strong effects on the epithelium [37]
it would be logical to assume that it may have an important role also in
ovarian cancer. Remarkably, although PTGFR levels are lower in ovarian
tumors than in normal ovary, ovarian cancer patients with higher PTGFR
mRNA levels exhibit lower survival probabilities than patients with lower
PTGFR levels (Suppl. Figure S13). These findings make PTGFR a poten-
tially interesting pharmacological target against ovarian cancer dissemina-
tion and metastasis.
The TGF superfamily plays an important role in ovarian function and
pathogenesis [38] while, remarkably, mutations in genes of this pathway
are infrequent in ovarian cancer [39]. Importantly, we observed TGFB1
upregulation in ovarian cancer. Others and we have demonstrated the
importance of TGF in ovarian cancer cell dissemination and metastasis
in the peritoneal cavity [29,40], the primary metastatic site of this type
of cancer [41]. We first describe here the induction of TGFB1 by PGF2a
in cancer cells and our observation supports one earlier publication observ-
ing this induction in healthy bovine corpus luteum [42]. Not surprisingly,
we found a strong correlation between the expression of TGFB1 and all
the components of the COX2PGF2aPTGFRNFAT pathway tested. We
are the first to report the association of Ca2+/Calcineurin/NFAT signaling
with the transcriptional control of TGFB1. We thus offer data that show
the convergence between two pathways of great importance in cancer pro-
gression. COX2 products, such as PGF2a, are able to induce TGFB1 tran-
scription. This could further contribute to explain many of the effects of
COX2 and PGs in the tumor setting, such as EMT [43], metastasis and
immune evasion [44].
As mentioned, ovarian tumors rarely acquire mutations in the TGF
pathway, although this cytokine is upregulated in tumors over normal tis-
sue. PMEPA1, already proposed to be a molecular switch that converts
TGF, normally a tumor suppressor, to a tumor promoter [12] could be
the responsible for this inconsistency. Indeed, we found PMEPA1 elevated
in most ovarian tumors, its expression correlating with that of TGFB1.
Remarkably, PMEPA1 is induced also by PGF2a/NFAT axis, as by
TGF, reaching a synergistic effect when activating both pathways.
PMEPA1 overexpression increased tumor cell growth both in vitro and
in vivo, as we demonstrate using different cell lines and in vivo tumor
models, while its knockdown had the opposite effect. Thus, silencing
PMEPA1 resulted in reduced tumor growth in vivo. Our results also sug-
gest that intraperitoneal dissemination and metastasis is strongly reduced
by PMEPA1 knockdown. Given the fact that intracellular TGF signaling
moderately decreased, switching from SMAD2/3 to SMAD1/5/8, we
believe that PMEPA1 expressing cells are able to affect the tumor stroma
without suffering the negative effects TGF could induce. Our data on the
protumoral effect of PMEPA1 in ovarian cancer are also supported by the
fact that high PMEPA1 mRNA levels are associated with lower survival
rate of ovarian cancer patients.
It has been proposed that mutations or loss of p53 modify TGF action
in ovarian cancer [45], although this seems to be independent to the effect
observed with PMEPA1, since this was found in both p53 wt (A2780) and
null cell lines (SKOV3).
PMEPA1 overexpression altered cell morphology, prompting a more
epithelial phenotype, although TGF production by the cells is increased.
This altered morphology could be due to the upregulation of Ecadherin
we observed. Indeed, PMEPA1 was able to elevate functional Ecadherin
levels and thus concentrate part of the catenin in the intercellular junc-
tions, while other epithelial markers failed to be induced. We demonstrate
that catenin remains in a cytoplasmic and/or membrane localization in a
PMEPA1 dependent manner, in agreement with a very recent publication
by Amalia et al., showing how PMEPA1 inhibited Wnt signaling through
catenin stability and nuclear localization regulation [46]. Ecadherin can be
degraded or downregulated upon different stimuli, as TGF [47], and thus
lose association with catenin, that could translocate to the nucleus.
SKOV3EV cells show catenin nuclear localization probably due to basal
autocrine TGF signaling [29] and absence of membrane Ecadherin. The
effect of PMEPA may be explained, not only by a decrease in the suppres-
sion of CDH1 by TGF, but potentially a decrease of Ecadherin endocyto-
sis and degradation. This is also supported by the fact that we found the
same epithelial morphology and catenin cytoplasmic localization when we
treated cells with a latencyassociatedpeptide, inhibiting TGF or using a
TGFR inhibitor. Another plausible explanation to this phenomenon could
be the fact that catenin can depend on SMAD3 to translocate to the
nucleus [48]. Indeed, we also found that the overexpression of PMEPA1
reduced nuclear SMAD2/3, as already described in other cell systems
[11,12,24].
It has been already shown that Ecadherin expression can have a positive
effect on tumor aggressiveness and metastasis [49], which would perfectly
agree with our results. Moreover, we observed that PMEPA1 overexpress-
ing cells, not only had elevated growth capacity on substrate, but also
anchorage independent growth, in accordance with previous reports
attributing this role to Ecadherin [50].
It is well established that Ecadherin expression and decreased cell
mobility are common epithelial cell characteristics, while upregulation of
Ncadherin, vimentin and zincfinger domain proteins (SNAI1/SNAIL,
SNAI2/SLUG), among others, are often linked to a mesenchymallike phe-
notype [51]. A notable case is the ovarian surface epithelial (OSE) cells, in
which overexpression of Ecadherin induces a number of epithelial charac-
teristics and markers associated with malignant transformation and tumor
progression [52]. Remarkably, both primary and metastatic ovarian carci-
nomas express Ecadherin, in contrast to normal ovarian surface epithe-
lium, which rarely expresses Ecadherin [53,54]. Further work should be
done to elucidate the detailed mechanisms through which PMEPA1
upregulates or avoids downregulation of Ecadherin and if these depend
exclusively on TGFR signaling. We believe this Ecadherin elevation is
not due to the lack of CDH1 suppression, since we were only able to over-
express Ecadherin in PMEPA1overexpressing but not in EV cells (data not
shown). On the other hand, although elevated Ecadherin expression was
observed because of PMEPA1 expression, cells also induced Vimentin
and ZEB1 at the same time. Moreover, in silico analysis of the TCGA
Ovarian cancer cohort showed that PMEPA1 mRNA levels correlate both
with CDH1 levels as well as with EMT gene signatures scores. This indi-
cates that PMEPA1 overexpressing cells could take advantage of both
epithelial and mesenchymal characteristics, which could be an explanation
of the aggressiveness of these cells. Interestingly, PMEPA1 effects on
growth can be observed only in ovarian carcinoma cell lines with mes-
enchymal or intermediate mesenchymal phenotype but not in OVCAR8
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cells that are classified as epithelial. This supports idea that the effects of
PMEPA1 in favoring an epithelial phenotype are linked to those on
growth advantages.
Using a highgrade ovarian tumor patient cohort, we found strong
PMEPA1 expression in most tumors, perfectly correlating with
Ecadherin and catenin high expression. Bigger cohorts, including lower
grade primary tumor biopsies should be used to confirm if PMEPA1 is
linked to metastasis and its prognostic value. All the above could indicate
that PMEPA1 can tweak TGF signaling while making tumor cells produce
more, upregulate Ecadherin protein levels and reduce catenin nuclear
localization, thus increasing cell plasticity and proliferation.
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